Mostrar el registro sencillo del ítem

dc.contributor.authorVidal Insua, Yolanda 
dc.contributor.authorDe La Cámara Gómez, Juan Cruz 
dc.contributor.authorBrozos Vázquez, Elena María 
dc.contributor.authorFernández Montes, Ana 
dc.contributor.authorVázquez Rivera, Francisca
dc.contributor.authorVillanueva Silva, María José 
dc.contributor.authorBarbazán García, Jorge
dc.contributor.authorMuinelo Romay , Laura
dc.contributor.authorCandamio Folgar, Sonia 
dc.contributor.authorAbalo Piñeiro, Alicia
dc.contributor.authorLópez López, Rafael 
dc.contributor.authorAbal Posada, Miguel 
dc.contributor.authorAlonso Alconada, Lorena
dc.date.accessioned2017-08-18T08:47:13Z
dc.date.available2017-08-18T08:47:13Z
dc.date.issued2017-06-13
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/28608814es
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486087/es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/9421
dc.description.abstractColorectal cancer (CRC) is one of the major causes of cancer-related deaths. Early detection of tumor relapse is crucial for determining the most appropriate therapeutic management. In clinical practice, computed tomography (CT) is routinely used, but small tumor changes are difficult to visualize, and reliable blood-based prognostic and monitoring biomarkers are urgently needed. The aim of this study was to prospectively validate a gene expression panel (composed of GAPDH, VIL1, CLU, TIMP1, TLN1, LOXL3 and ZEB2) for detecting circulating tumor cells (CTCs) as prognostic and predictive tool in blood samples from 94 metastatic CRC (mCRC) patients. Patients with higher gene panel expression before treatment had a reduced progression-free survival (PFS) and overall-survival (OS) rates compared with patients with low expression (p = 0.003 and p ≤ 0.001, respectively). Patients with increased expression of CTCs markers during treatment presented PFS and OS times of 8.95 and 11.74 months, respectively, compared with 14.41 and 24.7 for patients presenting decreased expression (PFS; p = 0.020; OS; p ≤ 0.001). Patients classified as non-responders by CTCs with treatment, but classified as responders by CT scan, showed significantly shorter survival times (PFS: 8.53 vs. 11.70; OS: 10.37 vs. 24.13; months). In conclusion, our CTCs detection panel demonstrated efficacy for early treatment response assessment in mCRC patients, and with increased reliability compared to CT scan.es
dc.description.sponsorshipACIS (Axencia de Coñecemento en Saude); SERGAS. Cofinanced ERDF Funds 2007–2013es
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshEarly Detection of Cancer*
dc.subject.meshNeoplastic Cells, Circulating*
dc.subject.meshDisease-Free Survival*
dc.subject.meshNeoplasm Metastasis*
dc.subject.meshSurvival Rate*
dc.subject.meshColorectal Neoplasms*
dc.titlePredicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Studyes
dc.typeArtigoes
dc.identifier.doi10.3390/ijms18061265
dc.identifier.essn1422-0067
dc.identifier.pmid28608814
dc.issue.number6es
dc.journal.titleInternational journal of molecular scienceses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Oncoloxía médicaes
dc.page.initialE1265es
dc.relation.publisherversionhttp://www.mdpi.com/1422-0067/18/6/1265es
dc.rights.accessRightsopenAccesses
dc.subject.cie10Tumor maligno del colon, parte no especificadaes
dc.subject.decssupervivencia sin enfermedad*
dc.subject.decstasa de supervivencia*
dc.subject.decsmetástasis neoplásica*
dc.subject.decsdetección precoz del cáncer*
dc.subject.decsneoplasias colorrectales*
dc.subject.decscélulas neoplásicas circulantes*
dc.subject.keywordCélulas tumorales circulanteses
dc.subject.keywordDetección temprana del cánceres
dc.subject.keywordCáncer colorrectal metastásicoes
dc.subject.keywordRespuesta al tratamientoes
dc.subject.keywordBiomarcadoreses
dc.typefidesArtigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number18es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional